Phase I Success for Shandong Xinhua’s OAB-14, Advancing to Phase IIa in Alzheimer’s Therapy
Shandong Xinhua Pharmaceutical Co., Ltd, a Chinese pharmaceutical company listed in Shenzhen (SHE: 000756), has...
Jiangsu Hengrui Pharmaceuticals Co., Ltd Announces Resignations of Two Deputy General Managers
Jiangsu Hengrui Pharmaceuticals Co., Ltd, a leading pharmaceutical company based in China and listed on...
Hunan Warrant Pharmaceutical’s ZG-002 Receives NMPA Approval for Clinical Trials in Plaque Psoriasis
Hunan Warrant Pharmaceutical Co., Ltd, a pharmaceutical company based in China and listed on the...
Allgens Medical Technology’s BonGold Receives Marketing Approval from Malaysia’s MDA
Allgens Medical Technology Co., Ltd, a Beijing-based innovator in regenerative medicine materials and implantable devices...
Ocumension Therapeutics to Repurchase Shares, Demonstrating Confidence and Commitment to Investor Rights
Ocumension Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock...
Novartis and Versant Ventures Launch Borealis Biosciences with a Focus on RNA Medicines for Kidney Diseases
Novartis (NYSE: NVS), a Swiss pharmaceutical heavyweight, has joined forces with the US venture capital...
UK MHRA Approves Eisai and Biogen’s Alzheimer’s Drug Leqembi, Despite NICE Reimbursement Rejection
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Leqembi (lecanemab),...
Ascentage Pharma’s 2024 Interim Results Highlight 477% YOY Revenue Growth and First-Ever Profitability
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced its 2024 interim...
3SBio Inc. Reports 16% YOY Revenue Growth in 2024 Interim Financial Report, Highlighting Biomedicine Segment Strength
3SBio Inc., a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1530),...
Hangzhou Kang Ming’s ClouDr Posts Strong Financial Growth with Diversified Solutions and P2M Strategy
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the moniker “ClouDr” on the Hong...
Everest Medicines Launches Trial for Personalized mRNA Cancer Vaccine EVM16 in Solid Tumors
Everest Medicines, a biopharmaceutical company based in China and listed on the Hong Kong Stock...
Regeneron’s Linvoseltamab Faces FDA Complete Response Letter, Awaiting Reinspection of Manufacturer
Regeneron Pharmaceuticals Inc., a leading biopharmaceutical company based in the US and listed on the...
Astellas Pharma Employee in China Formally Indicted on Espionage Suspicion
Astellas Pharma Inc., a Japanese pharmaceutical company listed on the Tokyo Stock Exchange (TYO: 4503),...
CK Life Sciences’ Halneuron Receives FDA Fast-Track Designation for Chemotherapy-Induced Neuropathic Pain
CK Life Sciences (HKG: 0775), a biopharmaceutical company headquartered in China, has received fast-track designation...
GSC to Distribute Hecin’s Innovative PCR and RT-PCR Solutions in Middle Eastern Markets
Gulf Scientific Corporation (GSC), a prominent life sciences service provider headquartered in Dubai, United Arab...
WuXi Biologics Reports Flat Revenues with Growth in Non-COVID-19 Projects in 2024H1 Financial Report
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) from China,...
Innovent Biologics’ Fulzerasib Receives NMPA Approval for Advanced NSCLC Treatment in China
Innovent Biologics Inc., a biopharmaceutical company based in China and listed on the Hong Kong...
China’s NHC and NHSA Intensify Efforts to Stabilize Drug Supply and Prices Amid Shortages
The National Health Commission (NHC) has published a report titled “Recent Work on Securing Supply...
China Commits to Optimizing Market Access for Emerging Sectors and Global Scientific Collaboration
The General Office of the Communist Party of China (CPC) Central Committee and the State...
Qilu Pharmaceutical’s Biosimilar Ranibizumab Receives NMPA Approval, Marking a First in China
Qilu Pharmaceutical, a Chinese pharmaceutical company, has announced that its biosimilar version of Novartis’s blockbuster...